Targeted Therapy Welfare Fund

Breast cancer is the most common cancer in women worldwide. The management of breast cancer is complex and is usually customized specifically for individual patients. 1 in 5 breast cancer patients is tested positive for Human Epidermal growth factor Receptor 2 (HER2). HER2 is a protein in the body that promotes the growth of cancer cells aggressively. For breast cancer patients who are HER2 positive, doctors often prescribe a drug called Trastuzumab alongside other treatments such as surgery, chemotherapy & radiotherapy to enhance the outcome of the treatment. This treatment, however, is very costly, and many patients could not afford to pay for it. As a result, some patients choose to go for unproven traditional treatments, which might cause bad outcome and recurrences.

The Targeted Therapy Welfare Fund for Breast Cancer is a corporate social responsibility (CSR) program initiated by Beacon Hospital and Roche Malaysia. The objective of this program is to reduce the financial burden of breast cancer patients by enabling them to gain access to targeted therapy (Trastuzumab). Under this program, eligible breast cancer patients are given access to this treatment at a subsidized rate. Patients are only required to pay RM2,500 per cycle for Trastuzumab treatment which is a fraction of the normal charges.

  1. Patients are required to consult oncologist as an outpatient (consultation charges apply) in Beacon Hospital.
  2. Once the treatment plan is established, the attending oncologist will then refer the case to Beacon’s CSR office for financial assessment and eligibility.
  3. It will take approximately 1 – 2 working days to process the application.
  4. Once the application is approved, the patient will be provided with a guarantee letter, which will enable the patient to get the treatment done at the agreed subsidized cost.

1. How do I apply and enrol in this programme?
Patients must first consult our oncologist as outpatient (consultation charges apply). The attending oncologist will then refer the case to Beacon’s CSR office for financial assessment and eligibility. It will take approximately 3-5 working days to process the application. We urge applicants to provide supporting documents promptly to avoid delays. Once the application is approved, the patient will be provided with a guarantee letter which will enable the patients to get the treatment done at the agreed subsidised cost.

2. How much do I need to pay for this treatment?
AYou will need to pay RM 2,500 per cycle for Trastuzumab treatment*.

3. I am not from Klang Valley, how can I enrol in this programme?
You may contact us via phone or email. Alternatively, you can get more information from your local support groups. You are still eligible to enrol for this programme despite residing outside of Klang Valley.

4. Am I still eligible for this programme, if I am a recipient of other CSR welfare funds by Beacon Hospital? 
You may be enrolled into more than one CSR Welfare Fund Programmes (e.g. Radiotherapy Welfare Fund, Chemotherapy Welfare Fund, etc) provided you meet the eligibility criteria.

5. How many cycles of Trastuzumab will I receive under this programme?
Typically, am adjuvant targeted therapy regime for breast cancer patients will comprise of 18 cycles (approximately one year). This is subject to the discretion of the attending oncologist.

6. What if I am required to take additional medications and/or investigations such as blood tests, booster injections, scans etc?
Under this programme, the cost of additional medications and/or investigations is to be borne by the patient*.

*Please refer to the programme coverage section.


This program includes:

  • Targeted therapy medicine (Trastuzumab) * subcutaneous
  • Day-care charges / Drug preparation / Medical consumables
  • Nursing charges / Monitoring equipment

This program does not include:

  • Doctor’s fee (RM150 per cycle only)
  • Lab tests (if needed)
  • Additional medication (if required)
  • Hospitalization/ Critical care (if required)
  1. This Welfare Fund is open to Malaysian citizens only.
  2. This Welfare Fund is for the patients who are low income, financially challenged, exhausted their finances or insufficient insurance coverage.
  3. Breast cancer patients seeking adjuvant targeted therapy (Trastuzumab) as prescribed by the attending oncologist in Beacon Hospital.
  4. Patients are diagnosed with early stage breast cancer.
  5. Non-palliative and/or metastatic cases.
  1. This program is open to Malaysian citizens only.
  2. This program is applicable to low income patients who are diagnosed with breast cancer.
  3. Applicants are required to fill up application form and submit with supporting documents to CSR department for assessment and approval.
  4. Beacon Hospital Sdn Bhd reserves the rights to amend the terms & conditions anytime without prior notice.

To date, all of our CSR programmes have already channeled more than RM 49 million in financial aid to help ease the burden faced by many underprivileged patients.

To apply for this Targeted Therapy Welfare Fund, patients can enquire at Beacon Hospital for further information. Interested applicants may apply by seeking advice from our CSR officer via phone call to +6012 328 6913  or email to

View Gallery